Kaleido Biosciences Inc (NASDAQ:KLDO) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 741,200 shares, a growth of 9.9% from the June 30th total of 674,300 shares. Approximately 8.4% of the company’s stock are short sold. Based on an average daily trading volume, of 59,100 shares, the short-interest ratio is currently 12.5 days.
Shares of KLDO traded down $0.31 during midday trading on Wednesday, hitting $8.58. The company had a trading volume of 30,007 shares, compared to its average volume of 65,780. The firm has a 50 day moving average price of $8.72. Kaleido Biosciences has a 52 week low of $6.23 and a 52 week high of $19.00.
Kaleido Biosciences (NASDAQ:KLDO) last released its earnings results on Thursday, August 1st. The company reported ($0.83) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.09). As a group, sell-side analysts expect that Kaleido Biosciences will post -2.81 earnings per share for the current year.
Several equities research analysts recently issued reports on KLDO shares. Zacks Investment Research downgraded shares of Kaleido Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, August 7th. Chardan Capital started coverage on shares of Kaleido Biosciences in a research note on Tuesday, April 23rd. They set a “buy” rating and a $17.50 price target on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $17.70.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC bought a new stake in shares of Kaleido Biosciences in the 2nd quarter worth about $56,000. Northern Trust Corp bought a new stake in shares of Kaleido Biosciences during the 2nd quarter valued at about $145,000. Menta Capital LLC bought a new stake in shares of Kaleido Biosciences during the 2nd quarter valued at about $164,000. Charles Schwab Investment Management Inc. bought a new stake in shares of Kaleido Biosciences during the 2nd quarter valued at about $353,000. Finally, Barometer Capital Management Inc. bought a new stake in shares of Kaleido Biosciences during the 1st quarter valued at about $443,000. 77.75% of the stock is owned by institutional investors.
About Kaleido Biosciences
Kaleido BioSciences, Inc develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infections caused by multi-drug resistant bacteria; chronic kidney disease; atherosclerotic cardiovascular disease; and drug or disease induced diarrhea.
Featured Story: Coverage Ratio
Receive News & Ratings for Kaleido Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kaleido Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.